Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
Trial details
- Registry ID
- NCT05696717
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as TD-9855
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System AtrophyNCT05696717 | Theravance Biopharma | Phase 3 | Active not recruiting | 2026-01Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |